文献速递传染病防控与疫情报告免疫规划

HIV-1 gp120-CD4嵌合亚单位疫苗IHV01的1a期随机对照试验安全性与免疫原性

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
PubMed 文献 · Vaccine · 2021-06-04

该1a期随机双盲安慰剂对照试验纳入65名健康成人,设75、150、300 µg三个剂量递增组,于第0、4、8、24周肌注IHV01(磷酸铝佐剂FLSC疫苗)。不良事件总发生率疫苗组与对照组无显著差异,多数疫苗相关不良事件为轻度,最常见为注射部位疼痛;所有受试者均产生抗IHV01抗体及抗CD4i表位抗体,并出现针对异源HIV-1 Env的抗体反应和T细胞反应。

要点

  • IHV01在75、150、300 µg剂量下均安全耐受,无疫苗相关严重不良事件。
  • 所有受试者均产生抗IHV01抗体和抗CD4i表位抗体。
  • 抗体可识别多种HIV-1毒株的CD4非配体结合Env抗原。

核心结论

  • IHV01疫苗在所有测试剂量下安全、耐受良好且具有免疫原性。
  • 疫苗可引发针对gp120上保守CD4i表位的广谱反应性体液免疫,并介导抗病毒功能。

研究设计与样本

  • 首次人体1a期随机、双盲、安慰剂对照研究,纳入65名健康成人志愿者。
  • 设三个剂量递增组:75 µg、150 µg和300 µg,于第0、4、8、24周肌注,末次免疫后随访24周。

主要发现

  • 不良事件总发生率疫苗组与对照组无显著差异,89%的疫苗相关不良事件为轻度,最常见为注射部位疼痛。
  • 无疫苗相关严重不良事件、因不良事件中止、偶发HIV感染或CD4计数显著下降。
  • 至末次接种,所有疫苗受试者均产生抗IHV01抗体并显示抗CD4i表位抗体。
  • 所诱抗体与多种HIV-1毒株的CD4非配体结合Env抗原反应。
  • 所有队列均可见针对异源感染细胞或gp120结合CD4+细胞的抗体依赖性细胞介导的细胞毒作用,以及抗gp120 T细胞反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4 chimeric vaccine construct was designed to present a highly conserved CD4-induced (CD4i) HIV-1 envelope structure that elicits cross-reactive anti-envelope humoral responses and protective immunity in animal models of HIV infection. IHV01 is the FLSC formulated in aluminum phosphate adjuvant. We enrolled 65 healthy adult volunteers in this first-in-human phase 1a randomized, double-blind, placebo-controlled study with three dose-escalating cohorts (75 µg, 150 µg, and 300 µg doses). Intramuscular injections were given on weeks 0, 4, 8, and 24. Participants were followed for an additional 24 weeks after the last immunization. The overall incidence of adverse events (AEs) was not significantly different between vaccinees and controls. The majority (89%) of vaccine-related AE were mild. The most common vaccine-related adverse event was injection site pain. There were no vaccine-related serious AE, discontinuation due to AE, intercurrent HIV infection, or significant decreases in CD4 count. By the final vaccination, all vaccine recipients developed antibodies against IHV01 and demonstrated anti-CD4i epitope antibodies. The elicited antibodies reacted with CD4 non-liganded Env antigens from diverse HIV-1 strains. Antibody-dependent cell-mediated cytotoxicity against heterologous infected cells or gp120 bound to CD4+ cells was evident in all cohorts as were anti-gp120 T-cell responses. IHV01 vaccine was safe, well tolerated, and immunogenic at all doses tested. The vaccine raised broadly reactive humoral responses against conserved CD4i epitopes on gp120 that mediates antiviral functions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chua JV, Davis C, Husson JS, et al. Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. Vaccine. 2021. PMID: 34099328. doi:10.1016/j.vaccine.2021.05.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。